Insys Therapeut (NASDAQ: INSY) reported Q1 EPS of $0.23, $0.05 worse than the analyst estimate of $0.28. Revenue for the quarter came in at $41.6 million versus the consensus estimate of $45.63 million.

"Our fifth consecutive quarter of top line growth was driven by continued market penetration of Subsys, our market-leading sublingual spray used to alleviate breakthrough pain for cancer patients. Our expanded sales and marketing efforts led to increased market share for Subsys, solidifying its position as the most prescribed transmucosal immediate-release fentanyl (TIRF) product on the market today," said Michael L. Babich, President and Chief Executive Officer. "We continue to aggressively execute our strategy to develop our pipeline of pharmaceutical cannabinoids and other innovative products candidates with the goal of further increasing shareholder value while meeting underserved medical needs."

For earnings history and earnings-related data on Insys Therapeut (INSY) click here.